The PSI – the Pharmacy Regulator is the statutory body responsible for regulating pharmacists and pharmacies in the public interest. One of the roles of the PSI is to promote professional practice by pharmacists. This is done in a variety of ways, including the issuing of statutory guidelines and sharing information for the benefit of patients and the wider health system.
The PSI issued Guidance to Support Transparency of Medicines Pricing and Fees for Pharmacy Services in October 2025, subsequent to a Ministerial request issued to the PSI in April 2025. The guidance was developed following input received from a range of stakeholders, including targeted patient participation, and feedback received during a public consultation. Implementation of the guidance is supported by engagement with stakeholders, including the IPU, and resources for pharmacists and the public are available on the PSI website
PSI recognised the need for a lead-in time for implementation, including the development of appropriate software and is collaborating with the sector to support and arrive at best practices for transparency. Engagement with stakeholders and management of queries is ongoing. The guidance is being implemented on a phased basis. Since 1 December 2025, pharmacies are required to display information about the cost of all professional services provided in the pharmacy, on a clear notice in a conspicuous place where a patient can see it. Work is currently ongoing to support pharmacies in offering a detailed receipt for each transaction.
PSI derives inspection authority from the provisions of Part 7 of the Pharmacy Act, which provides the spectrum and range of actions used for the purposes of ascertaining whether any offence under a relevant enactment, any breach of a code of conduct or any professional misconduct has been committed. Differing formats of inspections are utilised, and visits may be focused on a particular area or the general operation of the pharmacy, including inspection/compliance history, and may include systems inspections, focused/thematic inspections or re-inspections to a pharmacy where required. Since the introduction of the guidance in December, compliance has been assessed during 27 inspection visits, with 19 pharmacies displaying a pricing transparency notice for patients and the public. Pharmacies found to be non-compliant are required to and asked to confirm compliance within a specified timeframe.